Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pancreatic Metal Stents in Chronic Pancreatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02135809
Recruitment Status : Completed
First Posted : May 12, 2014
Last Update Posted : July 9, 2019
Sponsor:
Information provided by (Responsible Party):
Boston Scientific Corporation

Brief Summary:
The purpose of this study is to document the performance of a new Fully Covered Self Expanding Metal Stents (FCSEMS) for treatment of refractory pancreatic duct strictures in patients with painful chronic pancreatitis.

Condition or disease Intervention/treatment Phase
Refractory Pancreatic Duct Strictures Painful Chronic Pancreatitis Device: WallFlex Pancreatic Stent Not Applicable

Detailed Description:
This study is a prospective, single arm, pre-approval study. Treatment of 10 patients will take place at 1-3 clinical centers in two phases. Phase 1 will include treatment of five patients with a three month stent indwell period at one clinical center. Phase 2 will include treatment of five additional patients with a 3-6 month stent indwell period at 1-3 clinical centers. Expected duration of participation for each patient is approximately 27 months for Phase 1 and approximately 27-30 months for Phase 2. All patients, regardless of phase, will be followed for 24 months after stent removal. Post-removal follow-up visits will occur at 1, 3, 6, 12, 18 and 24 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Fully Covered Self Expanding Metal Stents (FCSEMS) for Refractory Pancreatic Duct Strictures in Patients With Chronic Pancreatitis
Actual Study Start Date : June 2014
Actual Primary Completion Date : June 2015
Actual Study Completion Date : March 30, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pancreatitis

Arm Intervention/treatment
Experimental: FCSEMS
Patients will receive the WallFlex Pancreatic Stent.
Device: WallFlex Pancreatic Stent
Temporary placement of the WallFlex Pancreatic Stent for treatment of refractory pancreatic duct strictures in patients with painful chronic pancreatitis. Stent will be removed after 3-6 months indwell.




Primary Outcome Measures :
  1. Decrease of pain caused by refractory benign pancreatic duct strictures secondary to chronic pancreatitis [ Time Frame: 3 months after study stent removal ]
    Clinical success defined as decrease of pain caused by refractory benign pancreatic duct strictures secondary to chronic pancreatitis 3 months after stent removal compared to baseline prior to stent indwell period.


Secondary Outcome Measures :
  1. Occurrence and severity of serious adverse events related to the stenting procedure, to the indwelling stent and/or to stent removal [ Time Frame: Duration of study participation, an average of 27-30 months ]
  2. Stent placement success [ Time Frame: Study Stent Placement Procedure ]
    Ability to deploy the stent in satisfactory position (Stent Placement Success). Satisfactory position is defined as the stent being across the stricture, without visible impaction at an angle and distal end visible into the duodenum.

  3. Type of additional intervention within pancreatic duct [ Time Frame: Duration of study participation, an average of 27-30 months ]
  4. Stent removal success [ Time Frame: Study Stent Removal ]
    Successful stent removal (Stent Removal Success) defined as ability to remove stent endoscopically (grasper, snare, stent-in-stent) without serious stent removal-related adverse events

  5. Change of pain medication intake [ Time Frame: Duration of study participation, an average of 27-30 months ]
    Change of pain medication intake (type of medication) from baseline to each follow-up visit.

  6. Number of device events [ Time Frame: Duration of study participation, an average of 27-30 months ]
    Device Events, including findings not associated with adverse events, such as but not limited to asymptomatic stent migration.

  7. Stricture resolution of pancreatic duct after stent removal [ Time Frame: Study Stent Removal ]
    Assessment of pancreatic duct after stent removal compared to baseline, including ERCP to document extent of stricture resolution, extent of resolution of ductal dilation above the treated dominant stricture, and presence or absence of secondary ductal strictures at the level of where the proximal edge of the stent was located

  8. For patients who proceed to surgery, impact of prior SEMS on surgical outcomes. [ Time Frame: Up to surgery ]
  9. Stent functionality [ Time Frame: Up to time of study stent removal,average of 3-6 months on study ]
    Stent functionality: Relief of pain caused by refractory benign pancreatic duct strictures secondary to chronic pancreatitis at 3 days, 2 weeks, 1 month, 2 months, 4 months (Phase 2 patients as applicable) and just prior to stent removal compared to baseline prior to stent placement, using established pancreatic pain score

  10. Stricture Resolution at stent removal [ Time Frame: Study Stent Removal ]
    Stricture Resolution at stent removal, defined as pancreatographic confirmation of drainage of injected contrast medium after stent removal without visible persistent stricture

  11. Time to Recurrence of Stricture [ Time Frame: Duration of study participation, an average of 27-30 months ]
    Time to Recurrence of Stricture, established in patients who had stricture resolution at stent removal and defined as time elapsed from stent removal till recurrence of pain with associated documentation of narrowing of pancreatic duct. Recurrence of stricture will be documented at the time it is identified and absence of stricture recurrence will be ascertained at 1, 3, 6, 12, 18 and 24 months after stent removal. Pain will be documented using an established pancreatic pain score.

  12. Reason for additional intervention within pancreatic duct [ Time Frame: Duration of study participation, an average of 27-30 months ]
  13. Timing of additional intervention within pancreatic duct [ Time Frame: Duration of study participation, an average of 27-30 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age 18 or older
  2. Willing and able to comply with study procedures and follow-up schedule and provide written informed consent to participate in study
  3. Chronic pancreatitis of Cremer Type IV (Segmental pancreatitis of the head of the pancreas). See Appendix for Cremer classifications.
  4. Improvement of pancreatic pain during previous placement of a single pancreatic plastic stent
  5. At least one of the following:

    • Abdominal pain most probably related to chronic pancreatitis
    • Recurrent dominant main pancreatic duct stricture in the head of the pancreas after prior indwell of pancreatic plastic stent(s) if pain score was available prior to preceding stent therapy. Recurrent stricture to be visually assessed at endoscopy and confirmed by recurrent main pancreatic duct dilatation at MRCP.
    • Relapsing pain due to pancreatic duct stent blockage (with only one stent in place)
  6. Prior endoscopic pancreatic sphincterotomy (EPS), historically or to be provided at time of SEMS placement with informed patient consent.

Exclusion Criteria:

  1. Strictures caused by malignancies
  2. Biliary strictures caused by chronic pancreatitis
  3. Perforated duct.
  4. Ansa pancreatica or H anatomy
  5. Pancreatic duct stenoses not located in the head of the pancreas
  6. Failed access during an attempted ERCP on a prior date
  7. Prior pancreatic metal stent(s)
  8. Concurrent ESWL (Extracorporeal Shock Wave Lithotripsy) during the same treatment session
  9. Patients for whom endoscopic techniques are contraindicated.
  10. Patients who are currently enrolled in another investigational study that would directly interfere with the current study, without prior written approval from the sponsor
  11. Inability or refusal to comply with the follow-up schedule including subject living at such a distance from the investigational center that

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02135809


Locations
Layout table for location information
Belgium
ULB Erasme Hospital
Brussels, Belgium, B-1070
Sponsors and Collaborators
Boston Scientific Corporation
Investigators
Layout table for investigator information
Principal Investigator: Jacques Devière, MD, PhD ULB Erasme Hospital

Layout table for additonal information
Responsible Party: Boston Scientific Corporation
ClinicalTrials.gov Identifier: NCT02135809     History of Changes
Other Study ID Numbers: E7093
First Posted: May 12, 2014    Key Record Dates
Last Update Posted: July 9, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatitis
Pancreatitis, Chronic
Constriction, Pathologic
Pancreatic Diseases
Digestive System Diseases
Pathological Conditions, Anatomical